The FDA approved Bristol-Myers Squibb's Opdivo, or nivolumab, 3 mg/kg, in combination with low-dose Yervoy, or ipilimumab, 1 mg/kg, as a treatment for patients ages 12 years and up who have certain types of metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan chemotherapy combination.
FDA approves BMS' combo for colorectal cancer indication
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.